The Team

Dr. Everson founded HepQuant in 2007 and has served as Chief Executive Officer of HepQuant since its inception. He was Professor of Medicine and Director of Hepatology at the University of Colorado, Denver.

Dr. Everson’s research has covered basic research and clinical hepatology, including bile acid and cholesterol metabolism, mechanisms of gallstone formation, effects of female steroid hormones on liver metabolism, hepatitis C, liver transplantation, polycystic disease, and quantifying the function of the liver with unique minimally invasive tests. He is a frequent invited speaker at medical conferences and he has published over 300 original peer-reviewed papers, books, and book chapters. Dr. Everson is a member of the American Association for the Study of Liver Diseases (AASLD), American Gastroenterological Association (AGA), American Society of Transplantation (AST), the International Liver Transplant Society (ILTS). He is past member of the Transplant Hepatology Committees of the American Board of Internal Medicine and Accreditation Council for Graduate Medical Education.

Dr. Everson earned a BS in chemistry from University of North Dakota. He earned his MD at from Weil Medical College of Cornell University in New York City, then completed his residency training in internal medicine at Creighton University School of Medicine. He completed his training in Gastroenterology and Hepatology at the University of Colorado Anschutz Medical Campus.

Randy Dietrich is president of HepQuant. With responsibility for commercialization and capitalization, Mr. Dietrich has been one of the major financial backers of HepQuant and has been active in its corporate development since its founding. Mr. Dietrich is concurrently CEO of Republic Financial Corporation. He has successfully directed the development, transformation, and commercialization of more than 20 businesses in a wide range of industries. During his more than 35-year tenure with Republic Financial, he has been instrumental in developing and building the Company’s Special Situations and Aviation divisions.

A founding ambassador of the Hepatitis C Caring Ambassador Program, Mr. Dietrich is a strong advocate for raising public awareness of health issues. The Caring Ambassadors Program encourages individuals with life changing or life-threatening diseases to take active roles in managing their health care and in supporting others with similar health issues.

Mr. Dietrich earned a Bachelor of Science in accounting from Wittenberg University in Springfield, Ohio.

Paige Nardi, MBA, joined the Company in June 2023 as Vice President of Market Access, with responsibility for reimbursement, billing and market access. Ms. Nardi was Executive Director of Market Access for Scipher Medicine, a precision immunology company. Prior to Scipher, she was VP of Sales at Evolve Pharmacy Solutions, a pharmacy benefits manager company. She served as Director of Managed Care for Biodesix, a precision oncology diagnostics company.

Ms. Nardi earned a BA in marketing management and Swedish from Augustana College and an MBA in Marketing Management from Benedictine University.

Brad Everson joined HepQuant in 2009 and serves as the Chief Business Development Officer. Mr. Everson is responsible for overseeing HepQuant’s Pharma Solutions business as well as strategic business development efforts. He brings over 20 years of  experience in various areas including strategic business development, technical sales, partnerships, fundraising, medical research and development, and entrepreneurship.

Mr. Everson earned his BA from the University of Colorado at Boulder, where he double majored in Mathematics and Psychology, with a minor in Chemistry. Additionally, he holds credentials from the Johnson Graduate School of Management at Cornell University.

Joellyn Enos is an experienced diagnostics leader specialized in commercial strategy, go-to-market planning, product launch, business operations, and development for IVD and LDT diagnostic tests for health providers and patients.  With foundational expertise in discovery research and product development, she has brought value to the molecular diagnostics and health technology space for over 20 years at meaningful organizations, including Spesana, Everly Health, Biodesix, and Exact Sciences.  In developing and introducing noninvasive colon cancer screening tests and blood-based diagnostics to support lung cancer diagnosis and treatment, she has worked closely with specialty and primary care practices as well as health systems and payers to capture the needs of these critical teams in support of improved patient care and outcomes.

Ms. Enos earned her Bachelor of Science degree in Bacteriology and a Master of Science degree in Biotechnology, each from the University of Wisconsin-Madison.

Touraj Shokati, PhD, joined HepQuant in May 2024 as Vice President of Clinical Laboratory Affairs, where he oversees clinical laboratory operations and ensures compliance with regulatory guidelines. Prior to this, he served as Director of Drug Metabolism and Pharmacokinetics and Supervisor of the UC Toxicology Department at iC42 Clinical Research and Development, University of Colorado Anschutz Medical Campus.

Dr. Shokati is a seasoned professional with extensive experience in drug metabolism, pharmacokinetics, and in vitro diagnostic devices. His career includes pivotal roles such as R&D Group Leader at Roche Diagnostics, Laboratory Director at TEQ Analytical Laboratories, and Director of Drug Metabolism & Pharmacokinetics at iC42. In these positions, he managed laboratory operations and led diverse scientific teams with varied expertise. Dr. Shokati has significant experience in establishing start-up analytical laboratories and implementing regulatory guidelines/standards.

Dr. Shokati earned his MS in Chemistry and PhD in Analytical Chemistry/Biochemistry from the University of Bremen, Germany, in 2005.

Dr. Imperial joined HepQuant as Chief Medical Officer in March 2025. Prior to her full-time role, she served on the company’s Scientific Advisory Board and contributed as a consultant and co-author on several publications.

She previously held senior medical positions at Fortrea (formerly Labcorp), Blade Therapeutics, Conatus Pharmaceuticals, Fibrogen, and Onyx. Earlier in her career, Dr. Imperial founded the Liver Transplant Program at California Pacific Medical Center, later relocating with her team to Stanford University/Lucile Packard Children’s Hospital, where she served as Associate Professor of Medicine and Pediatrics. A practicing hepatologist until recently, her clinical focus included chronic liver disease, end-stage liver disease, and liver transplantation. She has authored over 50 publications, including articles, papers, and book chapters.

Dr. Imperial holds a Bachelor of Science in Psychology from Thomas More College at Fordham University and earned her MD from New York Medical College. She completed her residency, chief residency, and fellowships in clinical nutrition and gastroenterology at New England Deaconess Hospital and California Pacific Medical Center (UCSF). She also completed a fellowship in liver transplantation at the University of Pittsburgh.